• The primary objective of the study is to evaluate the safety of Q-Cells^® transplantation into the posterior columns of the spinal cord in patients with Transverse Myelitis

•  

Transverse Myelitis (TM) is an inflammatory condition of the spinal cord that leads to demyelination. Use of a cellular therapeutic to supply oligoprogenitor cells to induce remyelination is proven in animal models.

Enrollment is planned for up to 9 subjects over 12 months. 3 subjects in each co hort. Each subject receives a single time point administration of Q-Cells^®: with 10 unilateral injections targeted to posterior columns of the spinal cord.  An observational period of each subject will be completed, before moving forward with next subject, and the next co hort.

Study data will be assessed for safety and activity after the last subject has completed the 9-month study visit.  Following the 9-month study period, subjects who consent will continue to be followed for safety and activity long-term in a separate protocol.

Involvement consists of Screening, Pre-operative/Treatment, and Post-treatment study periods.  Post treatment will be conducted at Study site only. 

Subjects must have the ability to undergo a laminectomy, and extensive immunosuppressive therapy for a prescribed period.  Subjects must be ASIA 2 (paralyzed), be able to complete MRI’s, and complete multiple follow-up visits.